APA (7th ed.) Citation

AL, D. S., R, R., S, S., JW, J., & J, R. (2023). Editorial: FGF21 as a therapeutic target for obesity and insulin resistance: from rodent models to humans. Frontiers in endocrinology, 14, 1253675. https://doi.org/10.3389/fendo.2023.1253675

Chicago Style (17th ed.) Citation

AL, De Sousa-Coelho, Rodriguez-Rodriguez R, Softic S, Jonker JW, and Relat J. "Editorial: FGF21 as a Therapeutic Target for Obesity and Insulin Resistance: From Rodent Models to Humans." Frontiers in Endocrinology 14 (2023): 1253675. https://doi.org/10.3389/fendo.2023.1253675.

MLA (9th ed.) Citation

AL, De Sousa-Coelho, et al. "Editorial: FGF21 as a Therapeutic Target for Obesity and Insulin Resistance: From Rodent Models to Humans." Frontiers in Endocrinology, vol. 14, 2023, p. 1253675, https://doi.org/10.3389/fendo.2023.1253675.